Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Opko Health ( (OPK) ) just unveiled an update.
On September 15, 2025, OPKO Health, Inc. completed the sale of certain assets of its subsidiary, BioReference Health, to Laboratory Corporation of America Holdings (Labcorp) for up to $225 million. This transaction, which includes BioReference’s oncology and clinical testing services, marks a strategic shift for OPKO, allowing it to focus on core clinical testing operations and the growth of its 4Kscore Test franchise, while Labcorp expands its oncology services portfolio.
The most recent analyst rating on (OPK) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Opko Health stock, see the OPK Stock Forecast page.
Spark’s Take on OPK Stock
According to Spark, TipRanks’ AI Analyst, OPK is a Neutral.
Opko Health’s overall stock score is primarily impacted by its financial performance, which is marked by declining revenues and profitability issues. Technical analysis provides some short-term bullish signals, but the long-term trend remains bearish. The valuation is unattractive due to negative earnings and lack of dividends. Strategic initiatives and asset sales offer potential for improvement, but financial challenges remain significant.
To see Spark’s full report on OPK stock, click here.
More about Opko Health
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company that aims to establish leading positions in large, rapidly growing markets by leveraging its expertise in discovery, development, and commercialization, along with its novel and proprietary technologies.
Average Trading Volume: 2,791,931
Technical Sentiment Signal: Sell
Current Market Cap: $1.11B
For an in-depth examination of OPK stock, go to TipRanks’ Overview page.